• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AptarGroup, Inc. Common Stock (NY: ATR )

    146.75 +1.12 (+0.77%)
    Official Closing Price Updated: 7:00 PM EST, Feb 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 348,660
    Open 146.16
    Bid (Size) 144.24 (1)
    Ask (Size) 148.64 (1)
    Prev. Close 145.63
    Today's Range 144.63 - 146.95
    52wk Range 135.96 - 178.03
    Shares Outstanding 65,959,499
    Dividend Yield 1.23%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
    The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and the reasons why. 
    Via Benzinga
    Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?
    Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade tariffs eroded risk appetite. 
    Via Benzinga
    Topics Economy World Trade
    Exposures Interest Rates Tariff

    Performance

    YTD
    -4.81%
    -4.81%
    1 Month
    -7.20%
    -7.20%
    3 Month
    -15.06%
    -15.06%
    6 Month
    -2.19%
    -2.19%
    1 Year
    +4.60%
    +4.60%

    More News

    Read More
    Earnings Scheduled For February 6, 2025
    Via Benzinga
    How Is The Market Feeling About AptarGroup?
    Via Benzinga
    $100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Top 3 Materials Stocks That Are Set To Fly This Month
    Via Benzinga
    Aptar Reports Fourth Quarter and Annual 2024 Results
    From AptarGroup, Inc.
    Via Business Wire
    Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    $100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Aptar Declares Quarterly Dividend and Announces 2025 Annual Meeting Details
    From AptarGroup, Inc.
    Via Business Wire
    Aptar Named One of America’s Most Responsible Companies by Newsweek for the Sixth Consecutive Year
    From AptarGroup, Inc.
    Via Business Wire
    Aptar Announces 2025 Quarterly Conference Call Dates
    From Aptar
    Via Business Wire
    Aptar to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025
    From AptarGroup, Inc.
    Via Business Wire
    How Is The Market Feeling About AptarGroup?
    Via Benzinga
    $1000 Invested In AptarGroup 20 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Aptar Named Among Top 50 of the ‘World’s Top Companies for Women 2024’ by Forbes
    From AptarGroup, Inc.
    Via Business Wire
    Aptar Reports Third Quarter 2024 Results
    From AptarGroup, Inc.
    Via Business Wire
    Aptar Awarded Federal Government Contract to Advance Novel Sterilization Technology for Medical Devices
    From AptarGroup, Inc.
    Via Business Wire
    How Is The Market Feeling About AptarGroup?
    Via Benzinga
    This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Aptar Announces New $500 Million Share Repurchase Authorization and Declares Quarterly Dividend
    From AptarGroup, Inc.
    Via Business Wire
    Aptar’s N-Sorb Nitrosamine Mitigation Solution Accepted to US FDA’s Emerging Technology Program
    From AptarGroup, Inc.
    Via Business Wire
    Green Day Has The Right Idea As September Seasonality Comes In Hot
    Via Talk Markets
    Topics ETFs
    Aptar’s Nasal Unidose System to Deliver neffy® (epinephrine nasal spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From AptarGroup, Inc.
    Via Business Wire
    ATR Stock Earnings: AptarGroup Beats EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.